DIMENSIONAL VERSUS NOSOGRAPHIC APPROACH TO ALZHEIMERS-DISEASE - THERAPEUTIC IMPLICATIONS

被引：2

作者：

DEROUESNE, C

JOUVENT, R

机构：

[1] Department of Neurology, Hôpital de la Salpêtriere and lNSERM, Paris

[2] NSERM, Paris

来源：

NEUROEPIDEMIOLOGY | 1990年 / 9卷 / 04期

关键词：

Alzheimer’s disease; Behavioral disturbances; Cognitive deficits; Therapeutic trials;

D O I：

10.1159/000110770

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Negative results in therapeutic trials in Alzheimer’s disease (AD) usually account for the nonefficacy of the presently tested drugs. However, methodological flaws in the design of these studies, related to the commonly used nosographic approach, can also be implicated in the lack of demonstration of beneficial results. With regard to the heterogeneity of clinical manifestations of AD, the interest of the dimensional, transnosographic approach to cognitive deficits and behavioral disturbances in dementia is suggested for these trials. Both approaches can also be combined, according to the presumed biochemical action of the tested drug in the preclinical studies and the aim of the trial. © 1990 S. Karger AG, Basel.

引用

页码：177 / 182

页数：6

共 23 条

[11]

Rossor M.N., Iversen L.L., Reynolds G.P., Mountjoy C.Q., Roth M., Neurochemical characteristics of early and late onset types of Alzheimer’s disease, Br Med J, 288, pp. 961-964, (1984)

[12]

Derouesne C., Rancurel G., Le Poncin-Lafitte M., Rapin J.R., Lassen N., Variability of cerebral blood flow defects in Alzheimer’s disease on <sup>123</sup>Iodoiso- propyl-amphetamine and Single Photon Emission Tomography, Lancet, (1985)

[13]

Haxby J.V., Heterogeneous patterns of regional cerebral metabolism in Alzheimer’s disease: Cross- sectional and longitudinal studies, Senile Dementias. 2nd International Symposium, 2, pp. 65-72, (1988)

[14]

Chui H.C., The significance of clinically defined subgroups of Alzheimer’s disease, J Neural Transm, pp. 57-68, (1987)

[15]

Hills M., Armitage P., The two-period cross-over clinical trial, Br J Clin Pharmacol, 8, pp. 7-20, (1979)

[16]

Guyalt G., Sackett D., Taylor W., Chong J., Roberts R., Pugsley S., Determining optimal therapy - Randomized trials in individual patients, N Engl J Med, 314, pp. 889-892, (1986)

[17]

Teri L., Borson S., Kiyak A., Yamagishi M., Behavioral disturbance, cognitive dysfunction and functional skill. Prevalence and relationship in Alzheimer’s disease, JAGS, 37, pp. 109-116, (1989)

[18]

Mohr E., Schlegel J., Fabbrini G., Williams J., Mou-Radian M., Mann U.M., Claus J.J., Feadio P., Chase T.N., Clonidine treatment of Alzheimer’s disease, Arch Neurol, 46, pp. 376-378, (1989)

[19]

Kopelman D.M., Multiple memory deficits in Alzheimer-type dementia: Implications for pharmacotherapy, Psychol Med, 15, pp. 527-541, (1983)

[20]

Weingartner H., Grafman J., Kaye W., Martin P.R., Forms of memory failure, Science, 221, (1983)

← 1 2 3 →